- Home
- KURA vs NRIX Comparison
KURA vs NRIX Comparison
Compare KURA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- NRIX
- Stock Information
- Founded
- KURA 2014
- NRIX 2009
- Country
- KURA United States
- NRIX United States
- Employees
- KURA N/A
- NRIX N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- NRIX Health Care
- Exchange
- KURA Nasdaq
- NRIX Nasdaq
- Market Cap
- KURA 700.5M
- NRIX 728.6M
- IPO Year
- KURA N/A
- NRIX 2020
- Fundamental
- Price
- KURA $8.22
- NRIX $9.91
- Analyst Decision
- KURA Buy
- NRIX Strong Buy
- Analyst Count
- KURA 14
- NRIX 15
- Target Price
- KURA $24.45
- NRIX $29.13
- AVG Volume (30 Days)
- KURA 2.0M
- NRIX 733.8K
- Earning Date
- KURA 11-06-2025
- NRIX 10-10-2025
- Dividend Yield
- KURA N/A
- NRIX N/A
- EPS Growth
- KURA N/A
- NRIX N/A
- EPS
- KURA N/A
- NRIX N/A
- Revenue
- KURA $83,279,000.00
- NRIX $88,381,000.00
- Revenue This Year
- KURA $60.25
- NRIX $74.59
- Revenue Next Year
- KURA $155.10
- NRIX N/A
- P/E Ratio
- KURA N/A
- NRIX N/A
- Revenue Growth
- KURA N/A
- NRIX 41.86
- 52 Week Low
- KURA $5.41
- NRIX $8.18
- 52 Week High
- KURA $21.40
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- KURA 66.50
- NRIX 47.82
- Support Level
- KURA $7.86
- NRIX $8.97
- Resistance Level
- KURA $8.52
- NRIX $9.68
- Average True Range (ATR)
- KURA 0.45
- NRIX 0.55
- MACD
- KURA 0.07
- NRIX 0.04
- Stochastic Oscillator
- KURA 80.89
- NRIX 55.13
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.